drugset / Trial / NCT00592943

PET Study Examining the Dopaminergic Activity of Armodafinil in Adults

NCT00592943

Phase 1/2 Completed 12 enrolled Massachusetts General Hospital
RandomizedParallel-groupOpen-label

Summary

The specific aims of this study are 1) to document the Dopamine Transporter (DAT) receptor occupancy of armodafinil using positron emission tomography (PET) scanning with C-11 altropane as the ligand and 2) to document the increased intrasynaptic dopamine produced by armodafinil using PET scanning with C-11 raclopride as the ligand. We hypothesize that DAT occupancy will be low with armodafinil; less than the DAT occupancy produced by therapeutic doses of methylphenidate. We also hypothesize that increases in intrasynaptic dopamine will be relatively low with armodafinil.

Timeline

Start
2007-10
Primary completion
2008-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Armodafinil Small molecule 100 mg Oral
Comparator Armodafinil Small molecule 250 mg Oral

Indications

No indication recorded.